• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小鼠 GPAT1 缺乏以模型依赖的方式调节 NASH 进展。

GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner.

机构信息

WRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.

WRDM Drug Safety, Research and Development, Pfizer Inc, Groton, Connecticut.

出版信息

Cell Mol Gastroenterol Hepatol. 2024;17(2):279-291. doi: 10.1016/j.jcmgh.2023.10.002. Epub 2023 Oct 14.

DOI:10.1016/j.jcmgh.2023.10.002
PMID:37844795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10829521/
Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), and its more severe form, nonalcoholic steatohepatitis (NASH), is the leading cause for liver failure and liver cancer. Although the etiology is likely multifactorial, genes involved in regulating lipid metabolism are enriched in human NAFLD genome-wide association studies (GWAS), pointing to dysregulated lipid metabolism as a major pathogenic factor. Glycerol-3-phosphate acyltransferase 1 (GPAT1), encoded by GPAM, converts acyl-CoAs and glycerol-3-phosphate into lysophosphatidic acid and has been shown to regulate lipid accumulation in the liver. However, its role in mediating the progression from NAFLD to NASH has not been explored.

METHODS

GPAT1-deficient mice were generated and challenged with diets inducing hepatic steatosis and NASH. Effects of GPAT1 deficiency on lipid and systemic metabolic end points were evaluated.

RESULTS

Ablating GPAT1 globally or specifically in mouse hepatocytes reduced hepatic steatosis in the context of diet-induced or genetic obesity. Interestingly, blunting of progression from NAFLD to NASH in global GPAT1 knockout (KO) mice was model dependent. GPAT1 KO mice were protected from choline deficient, amino acid defined high-fat diet-induced NASH development, but not from the high fat, high carbohydrate, and high cholesterol diet-induced NASH.

CONCLUSIONS

Our preclinical data support the notion that lipid metabolism pathways regulated by GPAT1 in hepatocytes play an essential role in NASH progression, albeit in a model-dependent manner.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)及其更严重的形式,即非酒精性脂肪性肝炎(NASH),是导致肝衰竭和肝癌的主要原因。尽管其病因可能是多因素的,但参与调节脂质代谢的基因在人类非酒精性脂肪性肝病全基因组关联研究(GWAS)中丰富,表明脂质代谢失调是主要的致病因素。甘油-3-磷酸酰基转移酶 1(GPAT1)由 GPAM 编码,将酰基辅酶 A 和甘油-3-磷酸转化为溶血磷脂酸,并已被证明可调节肝脏中的脂质积累。然而,其在介导从 NAFLD 向 NASH 进展中的作用尚未得到探索。

方法

生成了 GPAT1 缺陷型小鼠,并对其进行了诱导肝脂肪变性和 NASH 的饮食挑战。评估了 GPAT1 缺失对脂质和全身代谢终点的影响。

结果

全身性或特异性敲除 GPAT1 可减少饮食诱导或遗传肥胖小鼠的肝脂肪变性。有趣的是,全身性 GPAT1 敲除(KO)小鼠从 NAFLD 向 NASH 进展的减缓取决于模型。胆碱缺乏型、氨基酸定义型高脂肪饮食诱导的 NASH 发展中,GPAT1 KO 小鼠得到了保护,但在高脂肪、高碳水化合物和高胆固醇饮食诱导的 NASH 中则没有。

结论

我们的临床前数据支持这样的观点,即肝细胞中由 GPAT1 调节的脂质代谢途径在 NASH 进展中起着至关重要的作用,尽管在模型依赖性方面有所不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/bbf6fac6224c/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/52ee7bf0320a/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/0de1f3a3bc27/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/0a3fa0303426/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/1a1e5876a555/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/bb5ca42a5a41/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/cf6ca441296b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/473fec49ea41/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/bbf6fac6224c/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/52ee7bf0320a/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/0de1f3a3bc27/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/0a3fa0303426/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/1a1e5876a555/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/bb5ca42a5a41/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/cf6ca441296b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/473fec49ea41/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/bbf6fac6224c/gr7.jpg

相似文献

1
GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner.小鼠 GPAT1 缺乏以模型依赖的方式调节 NASH 进展。
Cell Mol Gastroenterol Hepatol. 2024;17(2):279-291. doi: 10.1016/j.jcmgh.2023.10.002. Epub 2023 Oct 14.
2
6-Gingerol Ameliorates Hepatic Steatosis via HNF4α/miR-467b-3p/GPAT1 Cascade.6-姜酚通过 HNF4α/miR-467b-3p/GPAT1 级联减轻肝脂肪变性。
Cell Mol Gastroenterol Hepatol. 2021;12(4):1201-1213. doi: 10.1016/j.jcmgh.2021.06.007. Epub 2021 Jun 15.
3
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.TXNIP/VDUP1 通过自噬和脂肪酸氧化来减轻脂肪性肝炎。
Autophagy. 2021 Sep;17(9):2549-2564. doi: 10.1080/15548627.2020.1834711. Epub 2020 Nov 16.
4
A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.高脂肪饮食和蛋氨酸-胆碱缺乏饮食动物模型中非酒精性脂肪性肝病基因表达谱的比较。
Molecules. 2022 Jan 27;27(3):858. doi: 10.3390/molecules27030858.
5
Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.肝星状细胞特异性 LOXL1 缺乏可消除非肥胖 NASH 小鼠的肝炎症、肝纤维化,并纠正脂质代谢异常。
Hepatol Int. 2021 Oct;15(5):1122-1135. doi: 10.1007/s12072-021-10210-w. Epub 2021 May 20.
6
The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.FATZO小鼠是2型糖尿病的下一代模型,在喂食添加了果糖的西式饮食时会发展为非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)。
BMC Gastroenterol. 2019 Mar 18;19(1):41. doi: 10.1186/s12876-019-0958-4.
7
Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.肝细胞中的 Tcf7l2 调控饮食诱导的非酒精性脂肪性肝病小鼠模型中的从头脂肪生成。
Diabetologia. 2023 May;66(5):931-954. doi: 10.1007/s00125-023-05878-8. Epub 2023 Feb 10.
8
Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.支链氨基酸可减轻胆碱缺乏高脂饮食诱导的非酒精性脂肪性肝炎(NASH)小鼠的肝脂肪变性和肝损伤。
Metabolism. 2017 Apr;69:177-187. doi: 10.1016/j.metabol.2016.12.013. Epub 2017 Jan 4.
9
Glycerol-3-phosphate Acyltransferase1 Is a Model-Agnostic Node in Nonalcoholic Fatty Liver Disease: Implications for Drug Development and Precision Medicine.甘油-3-磷酸酰基转移酶1是非酒精性脂肪性肝病中与模型无关的关键节点:对药物开发和精准医学的启示。
ACS Omega. 2020 Jul 16;5(29):18465-18471. doi: 10.1021/acsomega.0c02350. eCollection 2020 Jul 28.
10
Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis.肝脏再生增强因子缺陷导致非酒精性脂肪性肝炎和肝纤维化。
Hepatology. 2020 Nov;72(5):1586-1604. doi: 10.1002/hep.31167. Epub 2020 Oct 22.

引用本文的文献

1
Hepatic AKAP1 deficiency exacerbates diet-induced MASLD by enhancing GPAT1-mediated lysophosphatidic acid synthesis.肝脏AKAP1缺乏通过增强GPAT1介导的溶血磷脂酸合成加剧饮食诱导的代谢相关脂肪性肝病。
Nat Commun. 2025 May 8;16(1):4286. doi: 10.1038/s41467-025-58790-7.
2
Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment.代谢功能障碍相关脂肪性肝病的人类遗传学:从变异到病因再到精准治疗
J Clin Invest. 2025 Apr 1;135(7):e186424. doi: 10.1172/JCI186424.
3
The Emerging Role of LPA as an Oncometabolite.

本文引用的文献

1
Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease.全基因组关联荟萃分析确定了 17 个与非酒精性脂肪性肝病相关的位点。
Nat Genet. 2023 Oct;55(10):1640-1650. doi: 10.1038/s41588-023-01497-6. Epub 2023 Sep 14.
2
GPAM mediated lysophosphatidic acid synthesis regulates mitochondrial dynamics in acute myeloid leukemia.GPAM 介导的溶血磷脂酸合成调节急性髓系白血病中线粒体动力学。
Cancer Sci. 2023 Aug;114(8):3247-3258. doi: 10.1111/cas.15835. Epub 2023 May 17.
3
Structural basis of the acyl-transfer mechanism of human GPAT1.
LPA 作为一种致癌代谢物的新兴作用。
Cells. 2024 Apr 4;13(7):629. doi: 10.3390/cells13070629.
4
Fatty Acid Esterification as a NASH Therapeutic Target.脂肪酸酯化作为非酒精性脂肪性肝炎的治疗靶点
Cell Mol Gastroenterol Hepatol. 2024;17(2):311-312. doi: 10.1016/j.jcmgh.2023.10.011. Epub 2023 Nov 17.
人类GPAT1酰基转移机制的结构基础
Nat Struct Mol Biol. 2023 Jan;30(1):22-30. doi: 10.1038/s41594-022-00884-7. Epub 2022 Dec 15.
4
Multiomics study of nonalcoholic fatty liver disease.多组学研究非酒精性脂肪性肝病。
Nat Genet. 2022 Nov;54(11):1652-1663. doi: 10.1038/s41588-022-01199-5. Epub 2022 Oct 24.
5
A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation.一项针对不明原因慢性 ALT 升高(作为非酒精性脂肪性肝病的替代指标)的多祖裔全基因组关联研究,通过组织学和影像学验证。
Nat Genet. 2022 Jun;54(6):761-771. doi: 10.1038/s41588-022-01078-z. Epub 2022 Jun 2.
6
Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.通过药物靶点孟德尔随机化来描述脂质调节治疗的代谢组学特征。
PLoS Biol. 2022 Feb 25;20(2):e3001547. doi: 10.1371/journal.pbio.3001547. eCollection 2022 Feb.
7
Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials.非酒精性脂肪性肝炎(NASH)肝硬化:临床开发中治疗药物的快照及临床试验的最佳设计。
Expert Opin Investig Drugs. 2022 Feb;31(2):163-172. doi: 10.1080/13543784.2022.2032640. Epub 2022 Feb 10.
8
Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities.人类遗传学鉴定非酒精性脂肪性肝病的治疗靶点:挑战与机遇。
Front Endocrinol (Lausanne). 2021 Dec 7;12:777075. doi: 10.3389/fendo.2021.777075. eCollection 2021.
9
Lysophospholipid Mediators in Health and Disease.溶血磷脂脂质介质在健康和疾病中的作用
Annu Rev Pathol. 2022 Jan 24;17:459-483. doi: 10.1146/annurev-pathol-050420-025929. Epub 2021 Nov 23.
10
Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.线粒体甘油-3-磷酸酰基转移酶的遗传变异与肝损伤有关。
Hepatology. 2021 Dec;74(6):3394-3408. doi: 10.1002/hep.32038. Epub 2021 Nov 9.